CorylinCAS# 53947-92-5 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 53947-92-5 | SDF | Download SDF |
| PubChem ID | 5316097 | Appearance | Yellowish powder |
| Formula | C20H16O4 | M.Wt | 320.3 |
| Type of Compound | Flavonoids | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 100 mg/mL (312.17 mM) H2O : < 0.1 mg/mL (insoluble) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 3-(2,2-dimethylchromen-6-yl)-7-hydroxychromen-4-one | ||
| SMILES | CC1(C=CC2=C(O1)C=CC(=C2)C3=COC4=C(C3=O)C=CC(=C4)O)C | ||
| Standard InChIKey | PWAACAMQKVIVPZ-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C20H16O4/c1-20(2)8-7-13-9-12(3-6-17(13)24-20)16-11-23-18-10-14(21)4-5-15(18)19(16)22/h3-11,21H,1-2H3 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Corylin has a variety of pharmacological effects such as antioxidant, anti-proliferation, and anti-inflammatory properties, it may stimulate bone formation or have potential activity against osteoporosis. Corylin shows an inhibitory effect on IL-6-induced STAT3 promoter activity in Hep3B cells. |
| Targets | IL Receptor | NF-kB | STAT | Wnt/β-catenin |
| In vitro | Phenolic compounds isolated from Psoralea corylifolia inhibit IL-6-induced STAT3 activation.[Pubmed: 22573369]Planta Med. 2012 Jun;78(9):903-6.Inhibiting interleukin-6 (IL-6) has been postulated as an effective therapy in the pathogenesis of several inflammatory diseases. Aqueous extract of Psoralea corylifolia L. inhibits lipopolysaccharide-induced endothelial-mesenchymal transition via downregulation of the NF-κB-SNAIL signaling pathway.[Pubmed: 26238218 ]Oncol Rep. 2015 Oct;34(4):2040-6.The epithelial-mesenchymal transition (EMT) is a pivotal event in the invasion and metastasis of cancer cells. Psoralea corylifolia L. (PC) inhibits the proliferation of various cancer cells. However, its possible role in EMT has not been identified. |
| Kinase Assay | Comparison of the Inhibitory Potential of Bavachalcone and Corylin against UDP-Glucuronosyltransferases.[Pubmed: 24829606]Evid Based Complement Alternat Med. 2014;2014:958937.Bavachalcone and Corylin are two major bioactive compounds isolated from Psoralea corylifolia L., which has been widely used as traditional Chinese medicine for many years. As two antibiotic or anticancer drugs, bavachalcone and Corylin are used in combination with other drugs; thus it is necessary to evaluate potential pharmacokinetic herb-drug interactions (HDI) of the two bioactive compounds. |
Corylin Dilution Calculator
Corylin Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.1221 mL | 15.6104 mL | 31.2207 mL | 62.4415 mL | 78.0518 mL |
| 5 mM | 0.6244 mL | 3.1221 mL | 6.2441 mL | 12.4883 mL | 15.6104 mL |
| 10 mM | 0.3122 mL | 1.561 mL | 3.1221 mL | 6.2441 mL | 7.8052 mL |
| 50 mM | 0.0624 mL | 0.3122 mL | 0.6244 mL | 1.2488 mL | 1.561 mL |
| 100 mM | 0.0312 mL | 0.1561 mL | 0.3122 mL | 0.6244 mL | 0.7805 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Corylin is a major bioactive compound isolated from Psoralea corylifolia L; antibiotic or anticancer compound. IC50 value: Target: in vitro: Corylin showed an inhibitory effect on IL-6-induced STAT3 promoter activity in Hep3B cells with IC50 value of 1.37 uM [1].
References:
[1]. Lee SW, et al. Phenolic compounds isolated from Psoralea corylifolia inhibit IL-6-induced STAT3 activation. Planta Med. 2012 Jun;78(9):903-6.
- Apterin
Catalog No.:BCN3910
CAS No.:53947-89-0
- Euparone
Catalog No.:BCN7204
CAS No.:53947-86-7
- Crotalarine
Catalog No.:BCN2076
CAS No.:53937-97-6
- Deoxyarbutin
Catalog No.:BCC4774
CAS No.:53936-56-4
- Hederagenin 28-O-beta-D-glucopyranosyl ester
Catalog No.:BCN1423
CAS No.:53931-25-2
- (+)-Anabasine hydrochloride
Catalog No.:BCC7219
CAS No.:53912-89-3
- Pentostatin
Catalog No.:BCC1845
CAS No.:53910-25-1
- Nb-Feruloyltryptamine
Catalog No.:BCN3899
CAS No.:53905-13-8
- Tranilast
Catalog No.:BCC2514
CAS No.:53902-12-8
- Allicin
Catalog No.:BCN2347
CAS No.:539-86-6
- Perillen
Catalog No.:BCN6527
CAS No.:539-52-6
- Hordenine
Catalog No.:BCN1424
CAS No.:539-15-1
- Aristolactam AII
Catalog No.:BCN3924
CAS No.:53948-07-5
- Aristolactam BII
Catalog No.:BCN5717
CAS No.:53948-09-7
- Aristolactam BIII
Catalog No.:BCN5718
CAS No.:53948-10-0
- Glycyrrhizic acid ammonium salt
Catalog No.:BCN5943
CAS No.:53956-04-0
- Ginsenoside F1
Catalog No.:BCN1244
CAS No.:53963-43-2
- Luteolin 7,3'-di-O-glucuronide
Catalog No.:BCN5396
CAS No.:53965-08-5
- Z-Phg-OH
Catalog No.:BCC2795
CAS No.:53990-33-3
- Cefaclor
Catalog No.:BCC2527
CAS No.:53994-73-3
- L-Nicotine
Catalog No.:BCN6269
CAS No.:54-11-5
- Tryptophan
Catalog No.:BCN2615
CAS No.:54-12-6
- 5-Hydroxyindole-3-Acetic Acid
Catalog No.:BCC8285
CAS No.:54-16-0
- Sodium salicylate
Catalog No.:BCC4846
CAS No.:54-21-7
Comparison of the Inhibitory Potential of Bavachalcone and Corylin against UDP-Glucuronosyltransferases.[Pubmed:24829606]
Evid Based Complement Alternat Med. 2014;2014:958937.
Bavachalcone and Corylin are two major bioactive compounds isolated from Psoralea corylifolia L., which has been widely used as traditional Chinese medicine for many years. As two antibiotic or anticancer drugs, bavachalcone and Corylin are used in combination with other drugs; thus it is necessary to evaluate potential pharmacokinetic herb-drug interactions (HDI) of the two bioactive compounds. The aim of the present study was to compare the effects of liver UDP-glucuronosyltransferase (UGT) 1A1, UGT1A3, UGT1A7, UGT1A8, UGT 1A10, and UGT2B4 inhibited by bavachalcone and Corylin. 4-Methylumbelliferone (4-MU) was used as a nonspecific "probe" substrate. Bavachalcone had stronger inhibition on UGT1A1 and UGT1A7 than Corylin which did not inhibit UGT1A1, UGT1A3, UGT1A7, UGT1A8, UGT1A10, and UGT2B4. Data fitting using Dixon and Lineweaver-Burk plots demonstrated the noncompetitive inhibition of bavachalcone against UGT1A1 and UGT1A7-mediated 4-MU glucuronidation reaction. The values of inhibition kinetic parameters (Ki) were 5.41 mu M and 4.51 mu M for UGT1A1 and UGT1A7, respectively. The results of present study suggested that there was a possibility of UGT1A1 and UGT1A7 inhibition-based herb-drug interaction associated with bavachalcone and provided the basis for further in vivo studies to investigate the HDI potential between bavachalcone and UGT substrates.
Phenolic compounds isolated from Psoralea corylifolia inhibit IL-6-induced STAT3 activation.[Pubmed:22573369]
Planta Med. 2012 Jun;78(9):903-6.
Inhibiting interleukin-6 (IL-6) has been postulated as an effective therapy in the pathogenesis of several inflammatory diseases. In this study, seven flavonoids were isolated from the methanol extracts of Psoralea corylifolia by bioactivity-guided fractionation. The structures of bakuchiol (1), bavachinin (2), neobavaisoflavone (3), corylifol A (4), Corylin (5), isobavachalcon (6), and bavachin (7) were determined by spectroscopic analysis (1H-, 13C- NMR and MS). We demonstrated that compounds 1-7 showed an inhibitory effect on IL-6-induced STAT3 promoter activity in Hep3B cells with IC50 values of 4.57 +/- 0.45, 3.02 +/- 0.53, 2.77 +/- 0.02, 0.81 +/- 0.15, 1.37 +/- 0.45, 2.45 +/- 0.13, and 4.89 +/- 0.05 microMu, respectively. These compounds also inhibited STAT3 phosphorylation induced by IL-6 in Hep3B cells. Overall, several flavonoids from P. corylifolia might be useful remedies for treating inflammatory diseases by inhibiting IL-6-induced STAT3 activation and phosphorylation.
Aqueous extract of Psoralea corylifolia L. inhibits lipopolysaccharide-induced endothelial-mesenchymal transition via downregulation of the NF-kappaB-SNAIL signaling pathway.[Pubmed:26238218]
Oncol Rep. 2015 Oct;34(4):2040-6.
The epithelial-mesenchymal transition (EMT) is a pivotal event in the invasion and metastasis of cancer cells. Psoralea corylifolia L. (PC) inhibits the proliferation of various cancer cells. However, its possible role in EMT has not been identified. In the present study, we examined the effects of an aqueous extract of Psoralea corylifolia L. (PCAE), a typical medicinal decoction, on the EMT. Lipopolysaccharide (LPS) induced EMT-like phenotypic changes, enhancing cell migration and invasion. However, PCAE markedly reduced the expression of the LPS-induced EMT markers, including N-cadherin and vimentin, and increased the expression of beta-catenin. PCAE also inhibited cell migration and invasion in vitro. The effects of PCAE on the LPS-induced EMT were mediated by the inactivation of the NF-kappaB-SNAIL signaling pathway. The results provide new evidence that PCAE suppresses cancer cell invasion and migration by inhibiting EMT. Therefore, PCAE is a potentially effective dietary chemopreventive agent for malignant tumors since it inhibits metastasis.
